contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2406-rtx-as-expres2ion-biotechnologies-roblon-as-og-curasight

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Sales

Jesper Thomsen

RTX is an IT company that focuses on the development of wireless communication for industry and healthcare. The services include a wide range of cloud-based services, IP solutions, system integration, and radio systems. In addition, mechanical design is offered adapted for 3D and PABX-integrated solutions. Customers are found among small and medium-sized companies. RTX was founded in 1993 and is headquartered in Nørresundby, Denmark.

ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics.

The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Roblon develops high performance fiber solutions and technologies with a history dating back to 1957, when the company was founded.

Roblon produces the fibers, made of fiberglass, aramid etc. that are used to reinforce and protect vital cables in various industries.

The company is divided into two main business areas – Fiber Optic Cables (FOC) and Composite. The FOC segment is usually a sub-supplier to large cable producers, where the end customers are typically global internet and telecom providers. The Composite segment is usually a sub-supplier to the producers of wires and cables, which supply global oil & gas companies as well as companies that are active within wind energy.

Roblon is headquartered in Frederikshavn (Denmark) and has production facilities in Gærum (Denmark), Hickory, North Carolina (USA) and the recently acquired Vamafil in the Czech Republic. Roblon is thus active with production and sales in both Europe and the USA.

Roblon

Dagens aktienyheder med RTX A/S, ExpreS2ion Biotechnologies, Roblon A/S og Curasight

Dagens aktienyheder 24/06: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:8768" data-guid="9" data-object-urn="urn:li:organization:8768" data-original-text="RTX A/S" data-test-ql-mention="true">RTX A/S</a>, <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:823192" data-guid="10" data-object-urn="urn:li:organization:823192" data-original-text="ExpreS2ion Biotechnologies" data-test-ql-mention="true">ExpreS2ion Biotechnologies</a>, <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:84726" data-guid="12" data-object-urn="urn:li:organization:84726" data-original-text="Roblon A/S" data-test-ql-mention="true">Roblon A/S</a> og <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:9488709" data-guid="11" data-object-urn="urn:li:organization:9488709" data-original-text="Curasight" data-test-ql-mention="true">Curasight</a>
RTX var i g&#xe5;r eftermiddags ude med en opjustering af sine forventninger til det igangv&#xe6;rende regnskabs&#xe5;r 2024/25, bl.a. som f&#xf8;lge af bedre performance og en positiv udvikling i prim&#xe6;rt Enterprise segmentet, men ogs&#xe5; inden for Healthcare segmentet. Aktien lukkede i g&#xe5;r i kurs DKK 84 efter en stigning p&#xe5; 3,7% p&#xe5; dagen, og er i plus med n&#xe6;sten 50% &#xe5;r-til-dato. L&#xe6;s hele vores kommentar her: https://www.inderes.dk/analyst-comments/rtx-opjustering-af-forventningerne-til-202425
Expres2ion kunne i g&#xe5;r annoncere at de har doseret den f&#xf8;rste patient i det kliniske fase 1 fors&#xf8;g med deres brystkr&#xe6;ftkandidat ES2B-C00. L&#xe6;s mere her om fors&#xf8;get og tidslinje. https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-first-patient-dosed-in-phase-1-clinical-trial-of-es2b-c001
Efter regnskabet for H1 2024/25 fra Roblon i sidste uge, samt den nylige opjustering af hel&#xe5;rsforventningerne har vi opdateret vores one-pager p&#xe5; selskabet. Bliv klogere p&#xe5; Roblon her, og den aktuelle v&#xe6;rdians&#xe6;ttelse i forhold til peers: https://www.inderes.dk/research/roblon-upgrading-guidance-and-divesting-roblon-us-pre-their-h1-202425-report
Curasight: Offentliggjorde endeligt resultat af udnyttelsen af TO3 warrents i g&#xe5;r mandag efter b&#xf8;rsens lukning &#x2013; l&#xe6;s mere her: https://www.inderes.dk/analyst-comments/curasight-offentliggor-resultatet-af-udnyttelsen-af-to3-warrants
Disclaimer:&#xa0;<a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:54143576" data-guid="8" data-object-urn="urn:li:fsd_company:54143576" data-original-text="HC Andersen Capital" data-test-ql-mention="true">HC Andersen Capital</a> modtager betaling fra de n&#xe6;vnte selskaber for en Digital IR abonnementsaftale.
/Jesper Thomsen, d. 24/06-2025 kl. 08:58.

HC Andersen Capital

Dagens aktienyheder 24/06: RTX A/S, ExpreS2ion Biotechnologies, Roblon A/S og Curasight

Stay up to date